High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 13-18

  Freedman, Arnold S ^a   Neuberg, Donna ^a   Gribben, John G ^a   Mauch, Peter ^a   Soiffer, Robert J ^a   Fisher, David C ^a   Anderson, Kenneth C ^a   Andersen, Neils ^a   Schlossman, Robert ^a   Kroon, Mary ^a   Ritz, Jerome ^a   Aster, Jon ^a   Nadler, Lee M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; DISEASE COURSE; FEMALE; HUMAN; MALE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0031962090     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.13     Document Type: Article

References (43)

1. Lennert K: Centrocytic lymphoma, in Lennert K (ed): Histopathology of non-Hodgkin's Lymphoma. New York, NY, Springer-Verlag, 1981, pp 57-62
2. Weisenburger D, Kim H, Rappaport H: Mantle zone lymphoma: A follicular variant of intermediate lymphocytic lymphoma. Cancer 49:1429-1438, 1982
3. Swerdlow S, Beshaw, Murray J, et al: Centrocytic lymphoma: A distinct clinicopathologic and immunologic entity: A multiparameter study of 18 cases at diagnosis and relapse. Am J Pathol 113:181-197, 1983
4. Jaffe E, Bookman M, Longo D: Lymphocytic lymphoma of intermediate differentiation-mantle zone lymphoma. Hum Pathol 18:877-880, 1987
5. Weisenburger D, Sanger W, Armitage J, et al: Intermediate lymphocytic lymphoma: Immunophenotypic and cytogenetic findings. Blood 69:1617-1621, 1987
6. Perry D, Bast M, Armitage J, et al: Diffuse intermediate lymphocytic lymphoma. A clinicopathologic study and comparison with small lymphocytic lymphoma and diffuse small cleaved cell lymphoma. Cancer 66:1995-2000, 1990
7. Bookman M, Lardelli P, Jaffe E, et al: Lymphocytic lymphoma of intermediate differentiation: Morphologic, immunophenotypic, and prognostic factors. J Natl Canc Inst 82:742-748, 1990
8. Duggan M, Weisenburger D, Ye Y, et al: Mantle zone lymphoma: A clinicopathologic study of 22 cases. Cancer 66:522-529, 1990
9. Leith C, Spier C, Grogan T, et al: Diffuse small cleaved-cell lymphoma: A heterogeneous disease with distinct immunobiologic subsets. J Clin Oncol 10:1259-1265, 1992
10. Shivdasani R, Hess J, Skarin A, et al: Intermediate lymphocytic lymphoma: Clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma. J Clin Oncol 11:802-811, 1993
11. Banks P, Chan J, Cleary M, et al: Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 16:637-640, 1992
12. Harris N, Jaffe E, Stein H, et al: Perspective: A revised European-American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
13. Fisher R, Dahlberg S, Nathwani B, et al: A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including mucosal-associated lymphoid tissue and monocytoid B-cell subcategories): A Southwest Oncology Group study. Blood 85:1075-1082, 1995
14. Teodorovic I, Pittaluga S, Kluin-Nelemans J, et al: Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. J Clin Oncol 13:2819-2826, 1995
15. Berger F, Felman P, Sonet A, et al: Nonfollicular small B-cell lymphomas: A heterogeneous group of patients with distinct clinical features and outcome. Blood 83:2829-2835, 1994
16. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med 311:1471-1508, 1984
17. Meusers P, Engelhard M, Bartels H, et al: Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol 7:365-380, 1989
18. Zucca E, Fontana S, Roggero E, et al: Treatment and prognosis of centrocytic (mantle cell) lymphoma: A retrospective analysis of twenty-six patients treated in one institution. Leuk Lymphoma 13:105-110, 1994
19. Majilis A, Pugh W, Rodrigues M, et al: Three histologic variants of mantle cell lymphoma exhibiting striking heterogeneity in clinical behavior and biological features. Blood 82:388a, 1993 (suppl 1, abstr)
20. Zoldan M, Inghirami G, Masuda Y, et al: Large-cell variants of mantle cell lymphoma: Cytologic characteristics and p53 anomalies may predict poor outcome. Br J Haematol 93:475-486, 1996
21. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
22. Stewart D, Vose J, Weisenburger D, et al: The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 6:263-266, 1995
23. Khouri J, Romaguera J, Kantarjian H. et al: Hyper-CVAD and high dose methotrexate/ARA-C(HD MTX-ARA-C) followed by stem cell transplantation for aggressive mantle cell lymphoma. Blood 88:122a, 1996 (suppl 1, abstr)
24. Nademanee A, Molina A, Smith E, et al: High-dose therapy and autologous peripheral blood stem cell transplantation during first remission in patients with advanced stages and poor-prognosis mantle cell lymphoma. Blood 88:121a, 1996 (suppl 1, abstr)
25. Surbiguet C, Quachee M, Sebban C, et al: High dose chemotherapy in patients with mantle cell non Hodgkin's lymphomas. Blood 88:568a, 1996 (suppl 1, abstr)
26. Freedman A, Takvorian T, Neuberg D, et al: Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: A pilot study. J Clin Oncol 11:931-936, 1993
27. Gribben J, Freedman A, Woo S, et al: All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275-3280, 1991
28. Rimokh R, Berger F, Delsol G, et al: Detection of the chromosomal translocation t(11: 14) by polymerase chain reaction in mantle cell lymphomas. Blood 83:1871-1875, 1994
29. Williams ME, Swerdlow SH, MeekerTC: Chromosome t(11;14) breakpoints in centrocytic lymphoma are highly localized at the bel-1 major translocation cluster. Leukemia 7:1437-1440, 1993
30. Freedman AS, Takvorian T, Anderson KC, et al: Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 8:1-8, 1990
31. Kaplan E, Meier O: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
32. Mantel N: Evaluation of statistical data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
33. Velders G, Kluin-Nelemans J, De Boer C, et al: Mantle-cell lymphoma: A population-based clinical study. J Clin Oncol 14:1269-1274, 1996
34. Andersen N, Donovan J, Borus J, et al: Failure of immunologic purging in mantle cell lymphoma assessed by PCR detection of minimal residual disease. Blood 90:4212-4221, 1997
35. Gribben JG, Freedman AS, Neuberg D, et al: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325:1525-1533, 1991
36. Freedman A, Gribben J, Neuberg D, et al: High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88:2780-2786, 1996
37. Gribben J, Neuberg D, Freedman A, et al: Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81:3449-3457, 1993
38. Gribben J, Neuberg D, Barber M. et al: Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 83:3800-3807, 1994
39. Philip T, Armitage JO, Spitzer G, et al: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498, 1987
40. Phillips G, Fay J, Herzig R, et al: The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autolo-gous marrow transplantation. Blood 75:831-838, 1990
41. Gribben J, Saporito L, Barber M, et al: Bone marrow of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood 80:1083-1089, 1992
42. Press O, Eary J, Appelbaum F, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993
43. 43.' Press O, Eary J, Applebaum F, et al: Phase II trial of 131-B1 (anti-Cd20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340, 1995